Related Experiment Video
Updated: Jul 13, 2026
10:28
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
Published on: April 3, 2021
Skeletal myoblasts as a therapeutic agent
1Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Department of Cardiovascular Surgery, University Paris-Descartes, Faculté de Médecine, INSERM U 633, Paris, F-75015, France. philippe.menasche@gp.php.fr
Progress in Cardiovascular Diseases
|July 17, 2007
Summary
Cell transplantation using skeletal myoblasts shows promise for cardiac failure by improving heart function. Further research is needed to optimize delivery, cell purity, and survival for therapeutic use.
Area of Science:
- Regenerative Medicine
- Cardiovascular Biology
- Cell Therapy
Background:
- Cardiac failure significantly impacts patient outcomes.
- Cell transplantation aims to rejuvenate damaged heart tissue.
- Autologous skeletal myoblasts are a primary focus for clinical application.
Purpose of the Study:
- To evaluate the potential of cell transplantation in treating cardiac failure.
- To assess the engraftment, differentiation, and functional impact of myoblasts.
- To identify areas for improvement in cell therapy for cardiac repair.
Main Methods:
- Experimental studies documenting myoblast engraftment and differentiation.
- Phase I clinical trials assessing feasibility and safety.
- Ongoing large-scale randomized trials (e.g., MAGIC study) for efficacy validation.
Main Results:
- Myoblast transplantation demonstrates robust engraftment and differentiation into myotubes.
- Early clinical trials indicate feasibility and safety, with a note on potential arrhythmias.
- Functional improvements in left ventricular function have been observed.
Conclusions:
- Skeletal myoblast transplantation is a feasible and potentially effective therapy for cardiac failure.
- Optimizing cell purity, delivery methods, and cell survival is crucial for enhanced outcomes.
- Alternative cell types, such as cardiac-specified embryonic stem cells, may offer greater potential for myocardial regeneration.
More Related Videos
Related Concept Videos
01:21Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
01:13Formation of Muscle Fibers from Myoblasts
De novo myogenesis, or the formation of muscle fibers, begins during the early embryonic stages. The skeletal muscle is formed from somites– blocks of embryonic cell layers. The somites are further divided into dermatomes, myotomes, sclerotomes, and syndetomes. Among these, the myotomes give rise to muscle fibers.
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription factors...
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription factors...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:28Classification of Skeletal Muscle Relaxants
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...